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ABSTRACT 
 
The aim of the present study was to develop the simple, selective, rapid, precise and economical reverse 
phase-high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of 
levocetirizine and phenylpropanolamine HCl in solid dosage forms. The method was carried out on a 
Phenomenex Luna C18 (25 cm × 4.6 mm i.d., 5 μ) column with a mobile phase consisting of acetonitrile: 
0.5% triethylamine (70:30 v/v, pH 3.0) at a flow rate of 1.2 mL/min. Detection was carried out at 220 nm. 
The retention time (RT) 1.8 min and 2.6 min for phenylpropanolamine hydrocholride and levocetrizine 
respectively. The % recovery of standard phenylpropanolamine hydrocholride and levocetrizine was found 
to be 98.17 to 103.56 and 98.893 to 10.422 respectively. The % recovery of sample phenylpropanolamine 
hydrocholride and levocetrizine was found to be 101.30 and 100.63 respectively. The validation of the 
proposed method was also carried out. The proposed method can be used for the estimation of these drugs 
in combined dosage forms. 
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INTRODUCTION 
Levocetirizine (LEVO) (Figure 1) is a non-sedative 
antihistamine (third generation) that are developed 
from cetirizine (second-generation antihistamine). 
LEVO is active enantiomer of cetirizine which is 
chemically 2-(2-(4-((R)-(4-chlorophenyl)-phenyl-
methyl) piperazin-1-yl) ethoxy) acetic acid 
dihydrochloride. LEVO is a highly effective drug with 
fewer side effects when compared to second 
generation drug, cetirizine. [1,2]  
Phenylpropanolamine (PPH) is benzemethanol, α-(1-
aminoethyl)-hydrochloride, (R*,S*)-, (±).(±) 
Norephedrine hydrochloride (Figure 2) which is a 
mainly indirect acting sympathomimetic drug with 
an action similar to ephedrine. It is orally 
administered for the treatment of nasal congestion, 
relief of cough, cold symptoms, control of the urinary 
incontinence in some patients and suppress appetite 
in the management of obesity.[3]  
 
Figure 1: Structure of levocetirizine 
 
Figure 2: Structure of phenylpropanolamine HCl 
Literature survey reveals that the a number of 
analytical methods have been reported for the 
estimation of LEVO and PPH as individual and 
combined dosage form with each other and with 
other combination of other drugs such as 
Spectrophotometry, potentiometry, capillary gas 
chromatography and HPLC method. [4-12] The aim of 
present work was to develop simple, sensitive, 
accurate, and precise methods for the simultaneous 
estimation of levocetirizine and 
phenylpropanolamine HCl in solid dosage forms for 
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routine analysis. The proposed method was validated 
according to ICH guidelines. [13] 
MATERIAL AND METHODS 
Apparatus and software: The Shimadzu HPLC 
system consisting Binary gradient pump (LC-20AD 
VP pump), mixer (SUS vp Assy (new), Rheodyne 
injector, PDA Multiple wavelength detector SPD -
M20A vp) and Hamilton syringe (all from Shimadzu, 
Kyoto Japan) was used. The separations were 
achieved on a Phenomenex Luna 5µ C18 (2) 100A, 
250X4.60mm, with UV detection at 220 nm. 
Analytical weighing balance (Shimadzu AUX 200) 
was used for weighing, sonicator (SONICA 2200MH), 
vacuum pump (model XI 5522050 of Millipore), 
Millipore filtration kit for solvents and sample 
filtration were used throughout the experiment. The 
LC solution software-multiple channel was used for 
acquisition, evaluation and storage of 
chromatographic data. 
Reagents and Pharmaceutical Preparations: LEVO 
and PPH were kindly gifted by Mepro 
Pharmaceuticals Ltd, Gujrat and Embiotic Ltd, 
Bangalore, Certified to contain 99.86% and 99.92% 
purity respectively. The drugs are used without 
further purification. All the solvents used in analysis 
were of HPLC grade. Lezyncet-D tablets (label claim 
5mg LEVO and 25mg PPH). 
Standard solutions of LEVO and PPH 
It was used stock solutions of LEVO and PPH 1mgmL-
1 in Acetonitrile: 0.5% Triethylamine (70:30 v/v, pH 
3.0). The working solutions were 0.08 mg mL-1 and 
0.10mg mL-1 prepared by transferring 2.0 mL and 4.0 
mL from respective stock solution to a 50 mL 
volumetric flask and completing to volume with 
mobile phase. 
Preparation of mobile phase: HPLC experiments 
were carried out using Binary pump. In one solvent 
reservoir Acetonitrile and in another 0.5% 
Triethylamine (70:30 v/v, pH 3.0) 
Pharmaceutical Sample solution: Lezyncet-D 
tablets were weighed accurately. An amount of the 
powder equivalent to content of one unit of tablet 
was dissolved separately in 60 ml of mobile phase. 
The solutions were sonicated for 10 min and filtered 
into a 100 ml volumetric flask through 0.45µ nylon 
membrane filter. The residue was washed 3 times 
with 10 ml of mobile phase, and then the volume was 
completed to 100 ml with the same solvent. These 
solutions were further diluted to 1:100 with mobile 
phase. The proposed RP-HPLC method was applied 
and the concentration of each component in the 
formulation was determined.  
RESULTS AND DISCUSSIONS 
Chromatography: The mobile phase in Acetonitrile: 
0.5% Triethylamine (70:30 v/v, PH 3.0) was selected, 
because it was found that it ideally resolve the peaks 
with retention time (RT) 1.8 min and 2.6 min for PPH 
and LEVO respectively and the same is shown in 
(Figure 3). Wavelength was selected by scanning 
both standard drugs over a wide range of wavelength 
200nm to 350nm. Both the components show 
reasonably good response at 220 nm.  
 
Figure 3: Chromatogram of LEVO and PPH 
 
Figure 4: Calibration curve of levocetrizine 
 
Figure 5: Calibration curve of Phenylpropanolamine 
hydrocholride 
Validation of HPLC method 
Validation of an analytical method is the process to 
establish by laboratory studies that the performance 
characteristic of the method meets the requirements 
for the intended analytical application. 
To check the validity (predictive ability) of the 
calibration models, the simultaneous analysis of the 
prediction set containing 16 samples of various 
concentrations (in triplicates) of LEVO and PPH was  
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Table 1: Composition of the concentrations and recoveries results 
S. No 
Concentration in µg/ml % Recovery % Error 
LEVO PPH LEVO PPH LEVO PPH 
1 8 20 99.05 104.15 -0.95 4.15 
2 8 40 100.52 99.89 0.52 -0.11 
3 8 80 101.43 99.82 1.43 -0.18 
4 8 120 100.54 99. 76 0.54 -0.24 
5 16 20 102.74 102.35 2.74 2.35 
6 16 40 103.10 103.33 3.10 3.33 
7 16 80 101.01 99.68 1. 01 -0.32 
8 16 120 100.57 101.15 0.57 1.15 
9 24 20 99.62 98.89 -0.38 -1.11 
10 24 40 104.65 99.92 4.65 -0.08 
11 24 80 102.64 101.00 2.64 -1.00 
12 24 120 101.19 102.61 1.19 2.61 
13 44 20 100.09 101.35 0.09 1.35 
14 44 40 99.75 99.15 -0.25 0.85 
15 44 80 102.05 101.06 2.05 1.06 
16 44 120 101.64 98.94 1.47 1.06 
Mean recovery value 101.27 100.81 1.29 0.929 
%RSD 1.45 1.61   
Table 2: Linearity data for LEVO and PPH 
S. No 
Concentration of LEVO 
( g mL-1) 
Peak area 
Concentration of PPH 
( g mL-1) 
Peak area 
1 8 196001 20 87946 
2 16 383838 40 164709 
3 24 563397 50 210268 
4 32 721833 80 341086 
5 48 1053307 100 433252 
6 60 1291337 120 526906 
Table 3: Characteristic parameters of calibration equation for the proposed HPLC method for simultaneous 
determination of LEVO and PPH 
S.no Parameters LEVO PPH 
1 Correlation coefficient 0.999 0.999 
2 Calibration range (µg mL-1) 8 – 60 20-120 
3 Detection limit ( µg mL-1) 0.00028 0.0012 
4 Quantitation limit (µg mL-1) 0.00086   0.0038 
5 Regression equation (Y)a 0.997 0.9968 
6 Slope (b) 16967 4248.1 
7 Standard deviation of the slope (Sb) 16591 4147.3 
8 Intercept (a) 54754 743.44 
Table 4: Precision study results of prepared binary mixture 
Validation  HPLC  
parameter  % RSD  
Repeatabilitya    
LEVO 0.4011 0.93193 0.07646 
PPH 0.4739 0.26356 0.04844 
Intermediate 
precisionb 
Peak area Peak asymmetry Retention time 
LEVO 1.2549 0.75072 0.03893 
PPH 1.1821 0.39508 0.02174 
aRepeatability, three replicates of four concentration levels within-day 
bIntermediate precision, three replicates of four concentration levels between-days (3-days) 
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carried out and the mean recoveries and relative 
standard deviations of our proposed HPLC method 
was computed and indicated in (Table 1). Their 
numerical values were completely acceptable 
because of good recovery values and hence found 
satisfactory for the validation. 
Linearity 
The linearity of the proposed HPLC method for 
determination of LEVO and PPH was evaluated by 
analysing a series of different concentrations of 
standard drug. In this study six concentrations were 
chosen, ranging between 8-60 µg mL-1 of LEVO and 
20-120 µg mL-1 of PPH. Each concentration was 
repeated three times and obtained information on 
the variation in the peak area response ratio of the 
internal standard to pure analytes is presented in 
(Table 2, Table 3). Area is plotted graphically as a 
function of analyte concentration (Figure 4, Figure 5). 
The linearity of the calibration graphs was validated 
by the high value of correlation coefficient, slope and 
the intercept value. A linear relationship was 
obtained for LEVO and PPH in the range of 8-60 g mL-
1 and 20-120 g mL-1 respectively. 
Limit of detection (LOD) and limit of 
quantification (LOQ) 
The limit of detection (LOD) and limit of quantitation 
(LOQ) were calculated according to ICH (60) 
recommendations where the approach based on the 
signal-to-noise ratio. Chromatogram signals obtained 
with known low concentrations of analytes was 
compared with the signals of blank samples. A signal-
to-noise ratio 3:1 and 10:1 is considered for 
calculating LOD and LOQ respectively. The values of 
LOD and LOQ are given in (Table 5). 
Precision 
The precision of the analytical method was studied by 
analysis of multiple sampling of homogeneous 
sample. The precision expressed as % RSD is given in 
(Table 3). Method reproducibility was demonstrated 
by repeatability and intermediate precision 
measurements of peak area, retention time and peak 
symmetry parameters of HPLC method for each title 
ingredients. The repeatability (within-day in 
triplicates) and intermediate precision (for 3 days) 
was carried out at four concentration levels for each 
compound. The obtained results within and between 
days trials are in acceptable range indicating good 
precision of the proposed methods (Table 4). 
 
Accuracy 
The study was performed by increasing standard 
addition of known amounts of studied drugs to an 
unknown concentration (constant volume) of the 
commercial pharmaceutical formulations (Standard 
addition access the effect of a sample matrix changes 
the analytical sensitivity of the method). A constant 
volume of the unknown solution is added to each of 
three 10 mL volumetric flasks. Then a series of 
increasing volumes of working standard solutions 
are added. Finally, each flask is made up to the mark 
with solvent and mixed well. The concentration of the 
working standard solutions added should be chosen 
to increase the concentration of the unknown by 
minimum 30% in each succeeding flask. The resulting 
mixtures were analysed by the proposed HPLC 
methods and the response obtained was plotted 
against the initial unknown concentration set at 0. 
The results obtained are compared with expected 
results. The excellent mean recoveries and standard 
deviation (Table 5) suggested good accuracy of the 
propose methods and no interference from 
formulations recipients. 
Analysis of commercial formulations 
Applicability of the method was tested by analyzing 
the commercially available formulations containing 
the binary mixture of LEVO and PPH. The values of % 
recovery from formulation as shown in the (Table 6) 
are found to be very close to each other as well as to 
the label value of commercial pharmaceutical 
formulation, shows that the method is applicable for 
simultaneous determination of LEVO and PPH from 
their binary mixture formulation. 
(Lezyncet-D tablets label claim: 5 mg of LEVO and 25 
mg PPH per tablet), aMean recovery value of five 
determinations. bStandard deviation. 
Table 6: Results obtained for the pharmaceutical sam-





meana ± SDb 
LEVO 5 100.63 ± 0.104 
PPH 25 101.30 ± 0.19 
CONCLUSION 
Proposed study describes a new RP-HPLC method for 
the simultaneous determination of LEVO and PPH. 
For routine analytical purpose it is desirable to 
establish method capable of analyzing large numbers 
of samples in a short time period with good accuracy 
and precision without any prior separation step. The 
Table 5: Application of standard addition technique to the analysis of LEVO and PPH in Lezyncet-D tablets 
S. No 
Concentration of LEVO in µg/ml 
% recovery ± SD 
Concentration of PPH in µg/ml % recovery 
± SD Claimed Added Claimed Added 
1 5 0 100.63 ± 0.104 25 0 101.30 ± 0.19 
2 5 2 101.422 ± 0.050 25 4 98.17±0.150 
3 5 4 98.893 ± 0.315 25 8 103.56±0.197 
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developed method gives good resolution between 
both the compounds with a short analysis time (<4 
min). The method was validated and found to be 
simple, sensitive, accurate and precise. Percentage of 
recovery shows that the method is free from 
interference of the excipients used in the formulation. 
Therefore, the proposed method can be used for 
routine analysis of LEVO and PPH in their combined 
dosage form. 
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